AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29444231 — intervention group
Group type: EXPERIMENTAL
Intervention: MOR208, 12 mg/kg intravenously, weekly for 8 weeks, with possible extension based on response.
Number of subjects: 92
Study 29444349 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of depression and positive symptoms of psychosis (hallucinations and delusions)
Number of subjects: 404
Study 29444349 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive symptoms of psychosis (hallucinations and delusions)
Number of subjects: 404
Study 29444530 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine analgesia
Number of subjects: 300
Study 29444530 — intervention group
Group type: COMPARATOR
Intervention: Control (no morphine)
Number of subjects: 300
Study 29444644 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooper balloon catheter (geometric volume of 2.8 ml)
Number of subjects: 40
Study 29444644 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon pressure-volume (P-V) curves
Number of subjects: 40
Study 29444644 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of Ees and calibration of Pes
Number of subjects: 40
Study 29444644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bias in bench experiment
Number of subjects: 40
Study 29444649 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic thoracentesis (withdrawal of pleural fluid in portions of 200 ml up to 1000 ml and 100 ml above 1000 ml)
Number of subjects: 23
Study 29444650 — intervention group
Group type: EXPERIMENTAL
Intervention: LPG stove with behavioral intervention (Phase 1 and Phase 2)
Number of subjects: 50
Study 29444650 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention classes
Number of subjects: 50
Study 29444650 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based tailored behavioral intervention (Phase 2)
Number of subjects: 50
Study 29444659 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-to-left shunt (RLS) classified into four grades (Grade 0 to Grade III)
Number of subjects: 334
Study 29444659 — intervention group
Group type: EXPERIMENTAL
Intervention: Curtain RLS
Number of subjects: 334
Study 29444659 — intervention group
Group type: COMPARATOR
Intervention: No RLS
Number of subjects: 334
Study 29444695 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual rotation of the posterior position
Number of subjects: 238
Study 29444695 — intervention group
Group type: COMPARATOR
Intervention: Expectant management with no rotation
Number of subjects: 238
Study 29444926 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I measurement
Number of subjects: 1430
Study 29444926 — intervention group
Group type: COMPARATOR
Intervention: Pretest probability determined by the CAD Consortium risk model without cardiac troponin concentrations
Number of subjects: 1430
Study 29444998 — intervention group
Group type: EXPERIMENTAL
Intervention: Portico TAVI system
Number of subjects: 222
Study 29445030 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg orally daily until disease progression, withdrawal from study, or severe toxicity
Number of subjects: 8
Study 29445030 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg orally daily
Number of subjects: 8
Study 29445374 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial pulmonary fibrosis (FPF)
Number of subjects: 0
Study 29445374 — intervention group
Group type: EXPERIMENTAL
Intervention: Hermansky-Pudlak syndrome pulmonary fibrosis (HPSPF)
Number of subjects: 0
Study 29445374 — intervention group
Group type: COMPARATOR
Intervention: Unaffected relatives
Number of subjects: 0
Study 29445400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 3 × 400 IU
Number of subjects: 0
Study 29445400 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3 × 1 tablets
Number of subjects: 0
Study 29445520 — intervention group
Group type: EXPERIMENTAL
Intervention: AZL-M 40-mg
Number of subjects: 100
Study 29445520 — intervention group
Group type: EXPERIMENTAL
Intervention: AZL-M 80-mg
Number of subjects: 100
Study 29445520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29445521 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient engagement event to create an educational workbook
Number of subjects: 14
Study 29445536 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 357
Study 29445583 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab monotherapy
Number of subjects: 1
Study 29445858 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Thyroxine
Number of subjects: 41
Study 29445858 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 41
Study 29446481 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 261
Study 29446481 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa
Number of subjects: 261
Study 29446481 — intervention group
Group type: COMPARATOR
Intervention: kisspeptin
Number of subjects: 261
Study 29447240 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe periodontitis (SP)
Number of subjects: 15
Study 29447240 — intervention group
Group type: COMPARATOR
Intervention: Subjects without periodontitis (control group)
Number of subjects: 15
Study 29447926 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity enjoyment (PA enjoyment)
Number of subjects: 1721
Study 29448045 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PIVKA-II level measured by ARCHITECT immunoassay
Number of subjects: 892
Study 29448238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 119
Study 29448238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 29448849 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-molecule immune checkpoint inhibitors of PD-1/PD-L1
Number of subjects: 0
Study 29448849 — intervention group
Group type: COMPARATOR
Intervention: Antibodies binding to PD-1 or PD-L1
Number of subjects: 0
Study 29448936 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) administered by non-rebreather mask for up to 72 hours at 80 ppm
Number of subjects: 0
Study 29448936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29448936 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 29449135 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days/week before-school physical activity program
Number of subjects: 707
Study 29449135 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days/week before-school physical activity program
Number of subjects: 707
Study 29449135 — intervention group
Group type: COMPARATOR
Intervention: Nonparticipating children (control group)
Number of subjects: 707
Study 29449193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) treatment
Number of subjects: 20
Study 29449200 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth enabled nurse health coaching intervention (six scheduled health-coaching telephone calls, activity tracker, mobile application)
Number of subjects: 300
Study 29449200 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 300
Study 29449274 — intervention group
Group type: COMPARATOR
Intervention: Single-vessel moderate CAD (Group 2)
Number of subjects: 1136
Study 29449274 — intervention group
Group type: EXPERIMENTAL
Intervention: No apparent CAD (Group 1)
Number of subjects: 1136
Study 29449274 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivessel moderate CAD (Group 3)
Number of subjects: 1136
Study 29449274 — intervention group
Group type: EXPERIMENTAL
Intervention: Functionally significant CAD (Group 4)
Number of subjects: 1136
Study 29449294 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial overtreatment regimens in patients without pseudomonal infection risk factors
Number of subjects: 5828
Study 29449294 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical stability on admission
Number of subjects: 5828
Study 29449294 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of definite or probable pathogen
Number of subjects: 5828
Study 29449294 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration from clinical stability to discharge
Number of subjects: 5828
Study 29449294 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day mortality rate
Number of subjects: 5828
Study 29449294 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mortality risk patients with CURB-65 score 0-1
Number of subjects: 5828
Study 29449294 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mortality risk patients with Pneumonia Severity Index risk class I-II
Number of subjects: 5828
Study 29449298 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart hearing aids and a mobile phone application; a subset will also receive wearable biosensors.
Number of subjects: 1260
Study 29449298 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; existing data from clinical repositories.
Number of subjects: 1260
Study 29449367 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive assessment of load-independent RV contractility in HFpEF patients
Number of subjects: 24
Study 29449367 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive assessment of RV and left ventricular pressure-volume loops during basal conditions and handgrip exercise in HFpEF patients
Number of subjects: 24
Study 29449367 — intervention group
Group type: COMPARATOR
Intervention: Invasive assessment of RV and left ventricular pressure-volume loops in control patients without heart failure symptoms
Number of subjects: 24
Study 29449412 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic group (NYHA class I)
Number of subjects: 57
Study 29449412 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic group (NYHA class II and III)
Number of subjects: 57
Study 29449442 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine pressure wire assessment in all epicardial vessels of sufficient size to be amenable to revascularization
Number of subjects: 1100
Study 29449442 — intervention group
Group type: COMPARATOR
Intervention: Conventional angiography only
Number of subjects: 1100
Study 29449879 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Processing Therapy (CPT)
Number of subjects: 405
Study 29449879 — intervention group
Group type: COMPARATOR
Intervention: Individual support
Number of subjects: 405
Study 29449941 — intervention group
Group type: EXPERIMENTAL
Intervention: High-income countries (HI)
Number of subjects: 4378
Study 29449941 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-middle-income countries (UMI)
Number of subjects: 4378
Study 29449941 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-income countries (LI)
Number of subjects: 4378
Study 29449941 — intervention group
Group type: EXPERIMENTAL
Intervention: All national income groups
Number of subjects: 4378
Study 29449958 — intervention group
Group type: EXPERIMENTAL
Intervention: JOOL Health application
Number of subjects: 105
Study 29449958 — intervention group
Group type: EXPERIMENTAL
Intervention: JOOL Health application and Fitbit activity tracker and wireless-enabled scale
Number of subjects: 105
Study 29449958 — intervention group
Group type: COMPARATOR
Intervention: Information on prediabetes and evidence-based strategies to decrease progression to T2DM (comparison group)
Number of subjects: 105
Study 29450008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot-seat role
Number of subjects: 37
Study 29450008 — intervention group
Group type: COMPARATOR
Intervention: Observer role
Number of subjects: 37
Study 29450194 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS group (simultaneous cTOI and pTOI monitoring)
Number of subjects: 49
Study 29450194 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine monitoring and treatment)
Number of subjects: 49
Study 29450194 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS group (echocardiography performed due to NIRS measurements)
Number of subjects: 49
Study 29450722 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary endarterectomy
Number of subjects: 392
Study 29450722 — intervention group
Group type: COMPARATOR
Intervention: Targeted drug therapy
Number of subjects: 392
Study 29450722 — intervention group
Group type: COMPARATOR
Intervention: Balloon pulmonary angioplasty
Number of subjects: 392
Study 29450753 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mammography
Number of subjects: 9835
Study 29450753 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast MRI
Number of subjects: 9835
Study 29450753 — intervention group
Group type: COMPARATOR
Intervention: Lack of imaging
Number of subjects: 9835
Study 29450753 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of breast MRI
Number of subjects: 9835
Study 29451431 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 100
Study 29451431 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current
Number of subjects: 100
Study 29451431 — intervention group
Group type: EXPERIMENTAL
Intervention: Aussie current
Number of subjects: 100
Study 29451431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29451701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide (600 μg twice daily), Everolimus (10 mg/day), SIRT (SIR-Spheres dose on days 9 and 37)
Number of subjects: 13
Study 29451701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide, Everolimus, and SIRT
Number of subjects: 13
Study 29451706 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegAsp (insulin degludec and insulin aspart) twice daily
Number of subjects: 1808
Study 29451706 — intervention group
Group type: COMPARATOR
Intervention: BIAsp 30 (premixed insulin) twice daily
Number of subjects: 1808
Study 29451706 — intervention group
Group type: COMPARATOR
Intervention: IDeg + IAsp (insulin degludec once daily + insulin aspart)
Number of subjects: 1808
Study 29451806 — intervention group
Group type: EXPERIMENTAL
Intervention: High-wattage e-cigarettes
Number of subjects: 0
Study 29451806 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29452121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 mg b.i.d. initially, escalated to 10 mg b.i.d. for nonresponders)
Number of subjects: 12
Study 29452135 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised-exercise training (ET) interventions
Number of subjects: 0
Study 29452135 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions including supervised-ET
Number of subjects: 0
Study 29452135 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance ET at vigorous or moderate-to-vigorous intensities, with a volume ≥60 min/session and a frequency ≥3 sessions/week
Number of subjects: 0
Study 29452209 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolactin (PRL) treatment in FFA-induced HepG2 cells
Number of subjects: 456
Study 29452209 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolactin receptor (PRLR) overexpression in FFA-induced HepG2 cells
Number of subjects: 456
Study 29452209 — intervention group
Group type: COMPARATOR
Intervention: Silencing of PRLR
Number of subjects: 456
Study 29452209 — intervention group
Group type: COMPARATOR
Intervention: Overexpression of CD36
Number of subjects: 456
Study 29452209 — intervention group
Group type: COMPARATOR
Intervention: Comparison of serum PRL levels between NAFLD and non-NAFLD individuals
Number of subjects: 456
Study 29452209 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PRL levels in patients with severe vs mild-to-moderate hepatic steatosis
Number of subjects: 456
Study 29452351 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI) within 60 to 180 minutes from first medical contact
Number of subjects: 12675
Study 29452351 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 12675
Study 29452402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitotane monotherapy
Number of subjects: 127
Study 29452421 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-MS/MS measurement of cortisol at 30 minutes after intravenous administration of 250 µg tetracosactide acetate.
Number of subjects: 232
Study 29452421 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-MS/MS measurement of cortisol at 60 minutes after intravenous administration of 250 µg tetracosactine acetate.
Number of subjects: 232
Study 29452421 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-MS/MS measurement of 17-OHP at 30 minutes after intravenous administration of 250 µg tetracosactine acetate.
Number of subjects: 232
Study 29452421 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-MS/MS measurement of 17-OHP at 60 minutes after intravenous administration of 250 µg tetracosactine acetate.
Number of subjects: 232
Study 29452421 — intervention group
Group type: COMPARATOR
Intervention: Comparison of LC-MS/MS with routine immunoassays (Immulite and Roche platforms).
Number of subjects: 232
Study 29452808 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine administration during early resuscitation
Number of subjects: 38
Study 29452956 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face interaction
Number of subjects: 743
Study 29452956 — intervention group
Group type: COMPARATOR
Intervention: EMR review
Number of subjects: 743
Study 29452941 — intervention group
Group type: EXPERIMENTAL
Intervention: High-HDI countries
Number of subjects: 12539
Study 29452941 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-HDI countries
Number of subjects: 12539
Study 29452941 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-HDI countries
Number of subjects: 12539
Study 29452941 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 12539
Study 29452941 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SSI and resistant infections
Number of subjects: 12539
Study 29452941 — intervention group
Group type: EXPERIMENTAL
Intervention: High-HDI countries resistant infections
Number of subjects: 12539
Study 29452941 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-HDI countries resistant infections
Number of subjects: 12539
Study 29452941 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-HDI countries resistant infections
Number of subjects: 12539
Study 29452941 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor adjustment
Number of subjects: 12539
Study 29453190 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned monthly emails with content operationalizing anticipated regret, material incentive (behavior), and problem solving.
Number of subjects: 5576
Study 29453190 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 5576
Study 29453305 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose NOACs (1289 patients)
Number of subjects: 7925
Study 29453305 — intervention group
Group type: COMPARATOR
Intervention: Standard dose NOACs (6636 patients)
Number of subjects: 7925
Study 29454306 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/d until progression or intolerance
Number of subjects: 134
Study 29454321 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus, 25 mg IV weekly until progression, unacceptable toxicities or withdrawal
Number of subjects: 54
Study 29454321 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 54
Study 29454364 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporine A at 2.5 mg/kg/day
Number of subjects: 5
Study 29454380 — intervention group
Group type: EXPERIMENTAL
Intervention: Ministernotomy ("J" shaped upper hemisternotomy toward right 4th intercostal space)
Number of subjects: 100
Study 29454380 — intervention group
Group type: EXPERIMENTAL
Intervention: Ministernotomy
Number of subjects: 100
Study 29454380 — intervention group
Group type: COMPARATOR
Intervention: Full sternotomy
Number of subjects: 100
Study 29454592 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin (TLV)
Number of subjects: 433
Study 29454592 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (VAN)
Number of subjects: 433
Study 29454592 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin (TLV) for monomicrobial SA-HABP
Number of subjects: 433
Study 29454660 — intervention group
Group type: EXPERIMENTAL
Intervention: CATT treatment
Number of subjects: 1061
Study 29454762 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Ventricular Dysfunction (RVD)
Number of subjects: 1116
Study 29454762 — intervention group
Group type: COMPARATOR
Intervention: Normal RV function
Number of subjects: 1116
Study 29454767 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated MBF pixel maps
Number of subjects: 97
Study 29454776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance myocardial feature tracking (CMR-FT)
Number of subjects: 1235
Study 29454776 — intervention group
Group type: EXPERIMENTAL
Intervention: Global longitudinal strain
Number of subjects: 1235
Study 29454776 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-FT
Number of subjects: 1235
Study 29455032 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane administered with an expired fraction target of 2% during short-term procedural sedation.
Number of subjects: 24
Study 29455032 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-burn patients).
Number of subjects: 24
Study 29455308 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloids (6% hydroxyethyl starch HES 130/0.4)
Number of subjects: 4545
Study 29455308 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch HES 130/0.4
Number of subjects: 4545
Study 29455308 — intervention group
Group type: COMPARATOR
Intervention: Crystalloids only
Number of subjects: 4545
Study 29456073 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric low-carbohydrate diet with increased protein content
Number of subjects: 0
Study 29456073 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transcriptomic analysis
Number of subjects: 0
Study 29456445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Pain Threshold Scale (PPTS)
Number of subjects: 84
Study 29456445 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital pressure sensor and algometer
Number of subjects: 84
Study 29456529 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose immunosuppressive therapy combined with autologous CD34+ hematopoietic stem cell transplantation (AHSCT)
Number of subjects: 0
Study 29456529 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0